News

Number of submitted proposals - HORIZON-INFRA-2023-DEV-01, EOSC-01, SERV-01 and TECH-01 (call deadline 9 March 2023)

Published on | 2 years ago

Programmes Research Infrastructures

A total of 90 proposals were submitted to the 2023 research infrastructures calls with deadline 9 March 2023.

For the call HORIZON-INFRA-2023-DEV-01 Developing, consolidating and optimising the European research infrastructures landscape, maintaining global leadership (2023) a total of 47 proposals have been submitted. The breakdown per topics is the following:

 

For the call HORIZON-INFRA-2023-EOSC-01 Enabling an operational, open and FAIR EOSC ecosystem (2023) a total of 17 proposals have been submitted. The breakdown per topic is the following:

 

For the call HORIZON-INFRA-2023-SERV-01 Research infrastructure services to support health research, accelerate the green and digital transformation, and advance frontier knowledge (2023) 24 proposals have been submitted. The breakdown per topic is:

 

For the call HORIZON-INFRA-2023-TECH-01 Next generation of scientific instrumentation, tools, methods, and advanced digital solutions for RIs (2023) a total of 5 proposals have been submitted. The breakdown per topic is the following:

 

Evaluation results are expected to be communicated in July 2023.

Source: European Commission Funding and tender Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1784 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.